Cargando…
EASI p‐EASI: Predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers
Autores principales: | Bakker, Daphne S., Ariens, Lieneke F. M., Giovannone, Barbara, Hijnen, DirkJan, Delemarre, Eveline M., Knol, Edward, Nierkens, Stefan, de Bruin‐Weller, Marjolein S., Thijs, Judith L., Drylewicz, Julia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754122/ https://www.ncbi.nlm.nih.gov/pubmed/33305359 http://dx.doi.org/10.1111/all.14492 |
Ejemplares similares
-
Early identification of atopic dermatitis patients in need of systemic immunosuppressive treatment
por: Bakker, Daphne S., et al.
Publicado: (2019) -
New Developments in Biomarkers for Atopic Dermatitis
por: Thijs, Judith L., et al.
Publicado: (2015) -
Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry
por: ARIËNS, Lieneke F. M., et al.
Publicado: (2021) -
High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease
por: Achten, Roselie, et al.
Publicado: (2023) -
Conjunctival inflammation in dupilumab‐treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study
por: Bakker, Daphne S., et al.
Publicado: (2021)